[HTML][HTML] Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
J Cadranel, A Canellas, L Matton… - European …, 2019 - Eur Respiratory Soc
Immune checkpoint inhibitor-related pneumonitis (ICI-P) during cancer treatment is rarely
observed (<5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (…
observed (<5%). ICI-P is more often observed in patients with nonsmall cell lung cancer (…
Percutaneous image-guided electrochemotherapy of spine metastases: initial experience
…, M Ben Ammar, M Nouri-Neuville, L Matton… - CardioVascular and …, 2019 - Springer
Two patients underwent percutaneous image-guided electrochemotherapy on blastic spine
metastases involving posterior walls of the lumbar vertebral bodies with epidural extension. …
metastases involving posterior walls of the lumbar vertebral bodies with epidural extension. …
Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer–Case Report
P Wang, L Matton, F Kebir, K Kerrou, A Dubois… - Clinical Lung Cancer, 2022 - Elsevier
… Author links open overlay panel Pascal Wang 1 , Lise Matton 1 , Fatima Kebir 2 , Khaldoun
Kerrou 3 , Antonin Dubois 4 , Roger Lacave 5 , Jacques Cadranel 1 , Vincent Fallet 1 …
Kerrou 3 , Antonin Dubois 4 , Roger Lacave 5 , Jacques Cadranel 1 , Vincent Fallet 1 …
[HTML][HTML] Successful sequential tyrosine kinase inhibitors to overcome a rare compound of EGFR exon 18–18 and EGFR amplification: A case report
…, A Martin, K Chouahnia, A Benabadji, L Matton… - Frontiers in …, 2022 - frontiersin.org
Background: New mutational detection techniques like next-generation sequencing have
resulted in an increased number of cases with uncommon mutation and compound mutations (…
resulted in an increased number of cases with uncommon mutation and compound mutations (…
[HTML][HTML] Total Metabolic Tumor Volume on 18F-FDG PET/CT Is a Useful Prognostic Biomarker for Patients with Extensive Small-Cell Lung Cancer Undergoing First …
…, JB Assié, L Champion, N Girard, G Bonardel, L Matton… - Cancers, 2023 - mdpi.com
Simple Summary Chemotherapy with immune checkpoint inhibitors is the new standard of
care for first-line systemic therapy in extensive small-cell lung cancer. The identification of …
care for first-line systemic therapy in extensive small-cell lung cancer. The identification of …
[HTML][HTML] Local ablative therapy in oncogenic-driven oligometastatic non-small cell lung cancer: present and ongoing strategies—a narrative review
V Fallet, L Matton, A Schernberg… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Oligometastatic (OM) disease is defined by a low metastatic tumor spread. OM non-small cell
lung cancer (NSCLC) treatment aims to improve the patient’s prognosis and quality of life, …
lung cancer (NSCLC) treatment aims to improve the patient’s prognosis and quality of life, …
Strong ALK and PD-L1 positive IHC expression related ALK amplification in an advanced lung sarcomatoid carcinoma: A therapeutic trap?
S Gendarme, L Matton, M Antoine, K Kerrou… - Lung Cancer, 2021 - Elsevier
Objectives Immunohistochemistry (IHC) is considered as a screening method for ALK
rearrangement thanks to its excellent sensitivity. Strong marking on immunohistochemistry give the …
rearrangement thanks to its excellent sensitivity. Strong marking on immunohistochemistry give the …
Postoperative radiotherapy in non-small cell lung cancer stage IIIA-N2: Focus and perspectives
P Wang, B Duchemann, K Chouahnia, L Matton… - Bulletin du …, 2022 - europepmc.org
Patients with resectable stage IIIA-N2 lung cancer represent a very heterogeneous population
with variable risks of postoperative recurrence depending on the type of N2 involvement (…
with variable risks of postoperative recurrence depending on the type of N2 involvement (…
[PDF][PDF] Lire, écrire, prescrire: le point de vue des écrivaines et écrivains. Enquête
A Chassain, É Devevey, E Mouton-Rovira - Fabula LHT (Littérature …, 2023 - fabula.org
Ce texte est une enquête réalisée auprès de 16 auteurs et autrices sur les enjeux et usages
des formes prescriptives dans leur pratique littéraire. Il réunit les réponses de François Bon, …
des formes prescriptives dans leur pratique littéraire. Il réunit les réponses de François Bon, …
La radiothérapie postopératoire dans les cancers non à petites cellules de stade IIIA–N2: mise au point et perspectives
P Wang, B Duchemann, K Chouahnia, L Matton… - Bulletin du …, 2023 - Elsevier
Les patients avec cancer broncho-pulmonaire aux stades IIIA – N2 résécables représentent
un groupe hétérogène de malades avec des risques de récidives en postopératoire …
un groupe hétérogène de malades avec des risques de récidives en postopératoire …